The many thousands of plant species and their numerous chemical products make the study of CICD from plants appear daunting. The vast majority of CICD reactions, however, are caused by one of ...

During the past 20 years, the advent of neoadjuvant, primary, and adjuvant concurrent chemoradiotherapy has improved cancer care dramatically. Significant contributions have been made by ...

A comprehensive literature review was conducted for all medications on the formulary of Bedlam Clinic, a free evening clinic for the medically indigent or working poor, offered by the University ...

Estrogen agonists/antagonists are compounds with tissue-selective actions. The pharmacological goal of these compounds is to produce beneficial estrogenic actions in certain tissues (e.g., bone ...

Purpose: The pharmacology, pharmacokinetics, efficacy, safety, drug interactions, dosage and administration, cost, and place in therapy of duloxetine for major depression, pain from diabetic ...

Alendronate (Fosamax) reduces fracture rates among women with osteoporosis, usually defined as bone mineral density T-scores lower than -2.5. However, the benefit of alendronate in women with ...

Purpose: The purpose of this survey was to identify and characterize pharmacy productivity monitoring systems used in community hospitals that were part of a national group purchasing organization ...

Pamela J. Mccabe, PH.D., R.N.; Susan A. Barnason, PH.D., R.N.; Julia Houfek, PH.D., R.N. The association between stronger beliefs that the illness is caused by ...

The treatment of pseudoseizures has advanced greatly as comprehensive epilepsy centers have become widely accessible, with their capabilities for sophisticated electrophysiologic studies.

A variety of generalized and specific biochemical tests are available for symptomatic patients, which can assist with the initial diagnosis and assessment of required treatment, and may offer ...

Obe-cel was designed to increase T-cell persistence and reduce T-cell exhaustion and was shown to improve response rates and survival, particularly in patients with low leukemia burden.

Highlights in myasthenia gravis from AANEM 2024 include efficacy data on efgartigimod, ravulizumab, zilucoplan, and first-in-class inebilizumab, as well as safety outcomes in pregnancy for eculizumab.